What is the recommended evaluation and treatment for a patient presenting with allodynia?

Evaluation and Treatment of Allodynia

For a patient presenting with allodynia, initiate first-line pharmacological treatment with either a secondary-amine tricyclic antidepressant (nortriptyline or desipramine) OR a calcium channel α2-δ ligand (gabapentin or pregabalin), while simultaneously establishing the underlying cause of the neuropathic pain. 1

Initial Assessment

When evaluating allodynia, focus on:

• Sensory modality testing: Determine which stimuli trigger pain (light touch, pressure, pinprick, cold, or heat) as this affects 15-50% of patients with neuropathic pain and helps guide treatment 2
• Underlying etiology: Identify the cause—common culprits include postherpetic neuralgia, diabetic neuropathy, fibromyalgia, or post-surgical pain 3
• Comorbidities: Screen for cardiac disease (especially if considering TCAs), renal/hepatic dysfunction, depression, and gait instability as these influence medication selection and dosing 1
• Functional impact: Assess how allodynia affects activities of daily living and psychosocial functioning 4

The diagnosis is primarily clinical and does not require extensive testing beyond identifying the underlying neuropathic condition 3.

Pharmacological Treatment Algorithm

Step 1: First-Line Medications

Choose ONE of the following based on patient factors:

Option A: Tricyclic Antidepressants

• Start nortriptyline or desipramine at low doses at bedtime
• Titrate slowly over 6-8 weeks, including 2 weeks at maximum tolerated dose
• Keep dosage <100 mg/day when possible
• Obtain screening ECG for patients >40 years old
• Avoid in patients with ischemic cardiac disease or ventricular conduction abnormalities 1

Option B: Calcium Channel α2-δ Ligands

• Pregabalin: Start 150 mg/day in 2-3 divided doses, increase to 300 mg/day after 1-2 weeks (faster onset than gabapentin)
• Gabapentin: Titrate gradually up to 3600 mg/day in 3 divided doses; requires 2+ months for adequate trial
• Pregabalin provides more straightforward dosing with linear pharmacokinetics 1

Option C: For Localized Peripheral Allodynia

• 5% lidocaine patch: Excellent tolerability with minimal systemic absorption, particularly advantageous in elderly patients
• Most appropriate for well-localized peripheral neuropathic pain with allodynia
• Unlikely to benefit central neuropathic pain 1

Step 2: Assess Response at 4-6 Weeks

Monitor using the "Four A's" framework 4:

• Analgesia: Is pain reduced to ≤3/10?
• Activities: Has functional capacity improved?
• Adverse effects: Are side effects tolerable?
• Aberrant drug taking: Any concerning medication behaviors?

Step 3: Adjust Based on Response

If substantial pain relief (≤3/10) with tolerable side effects: Continue current regimen 1

If partial relief (pain ≥4/10) after adequate trial: Add a second first-line medication from a different class 1

If inadequate relief (<30% reduction) at target dose: Switch to an alternative first-line medication 1

Step 4: Second-Line Options for Refractory Cases

Tramadol or Opioid Analgesics

• Reserve for patients who fail first-line medications
• Exception: Use as first-line for acute neuropathic pain, cancer-related neuropathic pain, or episodic severe exacerbations 1
• Tramadol: Start 50 mg once or twice daily, increase by 50-100 mg/day every 3-7 days as tolerated, maximum 400 mg/day (300 mg/day if >75 years old)
• Monitor at least every 6 months for stable patients on strong opioids 4

Critical Pitfalls to Avoid

1. Don't wait indefinitely for response: Expect analgesic failure—patient response is highly individualistic. Stop medications that provide no or little response after adequate trial 4

2. Don't undertreate high-risk patients: Those at high risk of chronicity need review within 6 months and specialist assessment within 8-12 weeks if no improvement 4

3. Don't assume ongoing pain and allodynia share mechanisms: Evidence suggests these may involve different pathophysiologic processes (peripheral vs. central), so treating one may not resolve the other 5

4. Don't use lidocaine for central neuropathic pain: It's ineffective for centrally-mediated allodynia 1

When to Refer

Refer to a pain specialist or multidisciplinary pain center if:

• Trials of first-line medications alone and in combination fail 1
• Uncertain about the diagnosis of neuropathic pain 1
• No improvement after 8-12 weeks in high-risk patients 4
• Pain significantly impacts work capacity (shorten timeframe for specialist referral) 4